Pfizer and Valneva Initiate Phase III Study of Lyme Disease Vaccine Candidate VLA15

Pfizer, Inc. and Valneva SE announced the initiation of a Phase III clinical study, Vaccine Against Lyme for Outdoor Recreationists, to investigate the efficacy, safety, and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.